Wolverine Blend

Wolverine Blend” is not a single, chemically defined research peptide. It is a vendor-formulated combination product, informally named after the rapid regenerative healing factor of the Marvel Comics character Wolverine. Across the research-peptide supply industry, the name is commonly applied to mixtures of three individually characterized compounds associated with tissue-repair research: BPC-157, TB-500, and GHK-Cu. BPC-157 is a synthetic pentadecapeptide. TB-500 is a synthetic peptide corresponding to the actin-binding domain of thymosin beta-4. GHK-Cu is a copper-binding tripeptide.

“Wolverine Blend” is a marketing designation, not a peptide with its own CAS number, defined structure, or regulatory history. Because of this, the exact ratio, concentration, and even the specific constituents can vary between suppliers. No peer-reviewed study has evaluated this three-component combination as a single formulation. Everything summarized below is drawn from the separate published literatures on the individual constituents. Readers should not interpret this as evidence for the blend itself.

BPC-157 is a synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) first described by Sikiric and colleagues at the University of Zagreb in 1993. They described it as a partial sequence of a larger “body protection compound” identified in human gastric juice, developed as part of a stress-organoprotection research program (Sikiric et al., J Physiol Paris. 1993). TB-500 is a synthetic peptide sold as either the full sequence of thymosin beta-4 (Tβ4), or as a short fragment spanning its actin-binding motif (Ac-LKKTETQ). Tβ4 is a 43-amino-acid protein originally isolated from calf thymus tissue by Allan Goldstein’s group.

Tβ4 is the most abundant actin-sequestering protein in mammalian cells. GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). It was discovered by biochemist Loren Pickart in 1973 while studying age-related differences in the tissue-regenerative activity of human plasma. GHK-Cu concentrations in plasma are reported to decline from roughly 200 ng/mL in young adults to about 80 ng/mL by the sixth decade of life. Researchers have used this pattern to argue for a role in tissue maintenance (Pickart et al., Biomed Res Int. 2015).

Researchers are interested in this class of blend because each constituent independently affects processes relevant to wound and connective-tissue repair, angiogenesis, or extracellular matrix remodeling in preclinical models. This gives a plausible, though unproven, rationale for combining them in laboratory tissue-repair research.

1. BPC-157: nitric oxide and angiogenesis signaling

BPC-157 is proposed to promote vascular recruitment and angiogenesis partly through activation of the Src-caveolin-1-endothelial nitric oxide synthase (eNOS) pathway. In isolated rat aorta, BPC-157 produced concentration-dependent, endothelium-dependent vasodilation associated with increased Src, caveolin-1, and eNOS phosphorylation and reduced caveolin-1/eNOS binding (Vukojevic et al., Sci Rep. 2020). BPC-157 has also been reported to upregulate VEGFR2 expression and activate the FAK-paxillin pathway involved in endothelial and fibroblast migration (Chang et al., J Appl Physiol. 2011).

2. TB-500 (thymosin beta-4 fragment): actin sequestration and cell migration

The defining biochemical activity of Tβ4, and by extension the fragment marketed as TB-500, is 1:1 sequestration of monomeric G-actin. This regulates the pool of actin available for polymerization into filaments needed for cell motility. Tβ4 also activates integrin-linked kinase (ILK) and downstream Akt signaling, promoting cardiomyocyte and endothelial cell survival and migration after ischemic injury in mice (Bock-Marquette et al., Nature. 2004).

3. GHK-Cu: copper-dependent matrix remodeling

GHK-Cu modulates matrix metalloproteinases and their tissue inhibitors (TIMP-1, TIMP-2). It also stimulates synthesis of type I and III collagen, elastin, and glycosaminoglycans, and supports extracellular matrix turnover in dermal fibroblast systems (Pickart et al., Biomed Res Int. 2015). Because copper is a cofactor for lysyl oxidase and other collagen cross-linking enzymes, the copper-bound complex is considered mechanistically distinct from GHK alone.

No combined-formulation efficacy data exist for “Wolverine Blend.” The following summarizes constituent-specific evidence. None of it was generated using the marketed blend.

Cell Studies

BPC-157 increased outgrowth, survival under oxidative (H2O2) stress, and dose-dependent migration of cultured rat Achilles tendon fibroblasts, associated with FAK and paxillin phosphorylation (Chang et al., J Appl Physiol. 2011). Thymosin beta-4 stimulated keratinocyte and endothelial cell migration in scratch-wound assays, consistent with its actin-regulatory role. GHK-Cu stimulated fibroblast proliferation and upregulated genes for collagen, elastin, and proteoglycan synthesis in cultured human dermal fibroblasts (Pickart et al., Biomed Res Int. 2015).

Animal Studies

BPC-157 improved rat medial collateral ligament healing when given intraperitoneally (10 µg/kg or 10 ng/kg daily), topically (1.0 µg/g cream), or orally (0.16 µg/mL in drinking water). All three routes produced better functional and biomechanical outcomes than controls (Cerovecki et al., J Orthop Res. 2010). Thymosin beta-4 applied systemically or topically to full-thickness rat wounds increased re-epithelialization by up to 61% over saline controls by day 7. It also increased wound contraction, collagen deposition, and angiogenesis (Malinda et al., J Invest Dermatol. 1999). GHK-Cu accelerated wound healing and increased angiogenesis and antioxidant enzyme levels in rabbits. It also improved healing of ischemic and diabetic wounds in rats and mice.

Human Clinical and Cosmetic Studies

There are no published human trials of the combined blend. Human data on the individual constituents are limited. For BPC-157 in particular, such data are essentially absent from the peer-reviewed literature: no published, peer-reviewed randomized controlled trial of BPC-157 in humans exists for any indication. In 2023, the FDA added BPC-157 to its list of substances inappropriate for compounding, citing insufficient safety data and possible immune-response risk.

Thymosin beta-4, in an unrelated proprietary ophthalmic formulation (RGN-259), reached Phase 3 testing for neurotrophic keratopathy. One trial (SEER-1) showed significantly faster corneal healing than placebo, while a second Phase 3 trial (SEER-3) failed to meet its primary endpoint. A small pilot study in ten patients after ST-elevation myocardial infarction reported improved outcomes when endothelial progenitor cells were pretreated with thymosin beta-4 before transplantation.

However, this study used the endogenous protein under an investigational protocol, not the TB-500 fragment sold commercially. GHK-Cu has supporting data from small dermatologic and cosmetic trials reporting improvements in fine wrinkles and dermal density with topical creams, though sample sizes are modest.

No toxicology, pharmacokinetic, or safety data exist for the combined “Wolverine Blend” product. Because vendor formulations differ in ratio and concentration, findings for one labeled product cannot be generalized to another sold under the same name. For the constituents individually: BPC-157 lacks controlled human safety data and is the subject of an FDA warning regarding immune-response risk and impurities in compounded products.

Thymosin beta-4 has been studied under investigational protocols with generally favorable short-term tolerability in small trials, but long-term human safety data are absent. GHK-Cu applied topically at cosmetic concentrations is generally well tolerated in short-term trials. However, its metal-peptide complex is chemically unstable outside controlled formulations, and injectable or high-dose use has not been systematically studied. Because this product combines three distinct compounds, potential additive or interactive effects have not been investigated in any published study and cannot be excluded.

“Wolverine Blend” is an industry name for a vendor-defined mixture, most commonly BPC-157, TB-500, and GHK-Cu, rather than a validated single research compound. Each constituent has an independent preclinical literature suggesting roles in angiogenesis, actin-mediated cell migration, and collagen or matrix remodeling. Each also has at least some human data collected on the parent molecule or a related pharmaceutical formulation. None of that human evidence, however, was generated using the specific combined blend, dose, or ratio sold under this name.

No published study has tested whether combining the three produces additive, synergistic, or antagonistic effects. Preclinical evidence for the individual peptides is reasonably robust in rodent tissue-injury models. Translational and combination-specific evidence is essentially absent, and BPC-157 in particular currently carries an active FDA safety warning. This product should be treated as an unvalidated research mixture, not an evidence-based combination therapy. It is intended strictly for laboratory research, not for human or animal administration.

Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Frontiers in Pharmacology)

Thymosin β4 Accelerates Wound Healing (Journal of Investigative Dermatology)

Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Nature)

GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (PMC)

BPC-157: The peptide with big claims and scant evidence (STAT News)

Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-eNOS pathway (Scientific Reports)

1. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313-327. doi: 10.1016/0928-4257(93)90038-U.

2. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi: 10.1002/jor.21107.

3. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi: 10.1152/japplphysiol.00945.2010.

4. Vukojevic J, Siroglavic M, Kasnik K, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. doi: 10.1038/s41598-020-74022-y.

5. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi: 10.1046/j.1523-1747.1999.00708.x.

6. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466-472. doi: 10.1038/nature03000.

7. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2002;74(2):293-299. doi: 10.1006/exer.2001.1125.

8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. doi: 10.1155/2015/648108.

9. Pickart L, Margolina A. Skin regenerative and anti-cancer actions of copper peptides. Cosmetics. 2018;5(2):29. doi: 10.3390/cosmetics5020029.

10. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. doi: 10.3389/fphar.2021.627533.